PetVivo (PETV) 10-Q 16 Nov 20 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2020	Nov. 12, 2020
Cover [Abstract]
Entity Registrant Name	PetVivo Holdings, Inc.
Entity Central Index Key	0001512922
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,235,948
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Mar. 31, 2020
Current Assets
Cash and cash equivalents	$ 165,743	$ 888
Restricted cash		9,694
Accounts receivable	2,250	1,000
Equity sale proceeds receivable		52,000
Investments - equity securities	1,500	1,500
Prepaid expenses - short term	132,403	132,023
Total Current Assets	301,896	197,105
Property and Equipment:
Property and equipment	303,367	221,493
Less: accumulated depreciation	(125,548)	(111,586)
Total Property and Equipment, net	177,819	109,907
Other Assets:
Operating lease right-of-use	170,896	148,693
Prepaid expenses (net of current)	44,804
Trademark and patents, net	22,532	58,611
Security deposit	8,201	8,201
Total Other Assets	246,433	215,505
Total Assets	726,148	522,517
Current Liabilities
Accounts payable and accrued expenses	751,365	794,057
Accrued expenses - related party	21,270	252,607
Derivative liability	937,500
Convertible notes and accrued interest payable, net of debt discount	437,180	286,981
PPP loan - short term	22,839
Notes payable and accrued interest	42,825	15,095
Notes payable and accrued interest - related party	32,884	61,255
Operating lease liability - short term	26,363	24,791
Total Current Liabilities	2,272,226	1,434,786
Other Liabilities:
PPP loan (net of current)	15,988
Note payable and accrued interest - related party (net of current)	221,092
Operating lease liability (net of current)	144,533	123,901
Total Other Liabilities	381,613	123,901
Total Liabilities	2,653,839	1,558,687
Commitments and Contingencies
Stockholders' Equity (Deficit):
Preferred stock, par value $0.001, 20,000,000 shares authorized 0 and 0 shares outstanding at September 30, 2020 and March 31, 2020, respectively
Common stock, par value $0.001, 250,000,000 shares authorized 24,876,189 and 22,911,857 shares outstanding at September 30, 2020 and March 31, 2020, respectively	24,876	22,911
Common stock to be issued		52,000
Additional Paid-In Capital	54,798,088	53,477,564
Accumulated Deficit	(56,750,655)	(54,588,645)
Total Stockholders' Deficit	(1,927,691)	(1,036,170)
Total Liabilities and Stockholders' Deficit	$ 726,148	$ 522,517

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Mar. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	225,000,000	225,000,000
Common stock, shares issued	24,876,189	22,911,857
Common stock, shares outstanding	24,876,189	22,911,857

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenues	$ 4,790		$ 6,797
Cost of Sales	350	3,845	350	3,845
Gross Profit (Loss)	4,440	(3,845)	6,447	(3,845)
Operating Expenses:
Sales and Marketing	35,580	5,182	82,262	7,978
Research and Development		7,132		7,132
Intangible Impairment	11,971		15,577
General and Administrative:
Depreciation and Amortization	8,859	141,040	60,665	285,130
Other General and Administrative	766,597	272,415	1,108,578	619,250
Total General and Administration	775,456	413,455	1,169,243	904,380
Total Operating Expenses	823,007	425,769	1,267,082	919,490
Operating Loss	(818,567)	(429,614)	(1,260,635)	(923,335)
Other Income (Expense)
Gain on Sale of Asset			482	450
Gain on Debt Restructuring	516		516
Loss on Debt Extinguishment		(81,738)		(81,738)
Derivative Expense	(389,300)		(731,500)
Interest Expense	(140,651)	(7,821)	(170,873)	(15,437)
Total Other Expense	(529,435)	(89,559)	(901,375)	(96,725)
Net Loss before taxes	(1,348,002)	(519,173)	(2,162,010)	(1,020,060)
Income Tax Provision
Net Loss	$ (1,348,002)	$ (519,173)	$ (2,162,010)	$ (1,020,060)
Net Loss Per Share - Basic and Diluted	$ (0.06)	$ (0.03)	$ (0.09)	$ (0.05)
Weighted Average Common Shares Outstanding - Basic and Diluted	23,356,342	20,006,881	23,148,429	19,969,094

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Common Stock to be Issued [Member]	Total
Balance at Mar. 31, 2019	$ 22,074	$ 51,552,688	$ (52,505,912)	$ 86,333	$ (844,817)
Balance, shares at Mar. 31, 2019	19,867,200
Stock-based compensation		157,134		33,667	190,801
Net loss			(500,887)		(500,887)
Balance at Jun. 30, 2019	$ 22,074	51,709,822	(53,006,799)	120,000	(1,154,903)
Balance, shares at Jun. 30, 2019	19,867,200
Balance at Mar. 31, 2019	$ 22,074	51,552,688	(52,505,912)	86,333	$ (844,817)
Balance, shares at Mar. 31, 2019	19,867,200
Common stock issued, shares					1,763,872
Net loss					$ (1,020,060)
Balance at Sep. 30, 2019	$ 24,034	52,600,843	(53,525,972)	102,000	(799,095)
Balance, shares at Sep. 30, 2019	21,631,066
Balance at Jun. 30, 2019	$ 22,074	51,709,822	(53,006,799)	120,000	(1,154,903)
Balance, shares at Jun. 30, 2019	19,867,200
Common stock issued	$ 120	119,880		(120,000)
Common stock issued, shares	77,700
Common stock sold	$ 400	99,600			100,000
Common stock sold, shares	360,000
Stock-based compensation		135,278		102,000	237,278
Stock-based compensation, shares	30,300
Stock granted for debt conversion	$ 1,440	536,263			537,703
Stock granted for debt conversion, shares	1,295,866
Net loss			(519,173)		(519,173)
Balance at Sep. 30, 2019	$ 24,034	52,600,843	(53,525,972)	102,000	(799,095)
Balance, shares at Sep. 30, 2019	21,631,066
Balance at Mar. 31, 2020	$ 22,912	53,477,563	(54,588,645)	52,000	(1,036,170)
Balance, shares at Mar. 31, 2020	22,911,857
Common stock issued	$ 80	51,920		(52,000)
Common stock issued, shares	80,000
Warrants issued in conjunction with convertible debt		91,500			91,500
Stock-based compensation	$ 120	183,124			183,244
Stock-based compensation, shares	120,000
Net loss			(814,008)		(814,008)
Balance at Jun. 30, 2020	$ 23,112	53,804,107	(55,402,653)		(1,575,434)
Balance, shares at Jun. 30, 2020	23,111,857
Balance at Mar. 31, 2020	$ 22,912	53,477,563	(54,588,645)	52,000	$ (1,036,170)
Balance, shares at Mar. 31, 2020	22,911,857
Common stock issued, shares					466,086
Stock-based compensation					$ 837,107
Stock-based compensation, shares
Net loss					$ (2,162,010)
Balance at Sep. 30, 2020	$ 24,876	54,798,088	(56,750,655)		(1,927,691)
Balance, shares at Sep. 30, 2020	24,876,189
Balance at Jun. 30, 2020	$ 23,112	53,804,107	(55,402,653)		(1,575,434)
Balance, shares at Jun. 30, 2020	23,111,857
Common stock sold	$ 904	315,596			316,500
Common stock sold, shares	904,288
Stock-based compensation	$ 699	653,164			653,863
Stock-based compensation, shares	699,007
Stock granted for debt conversion	$ 100	25,282			25,382
Stock granted for debt conversion, shares	100,010
Cashless warrant exercises	$ 61	(61)
Cashless warrant exercises, shares	61,027
Net loss			(1,348,002)		(1,348,002)
Balance at Sep. 30, 2020	$ 24,876	$ 54,798,088	$ (56,750,655)		$ (1,927,691)
Balance, shares at Sep. 30, 2020	24,876,189

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss For The Period	$ (2,162,010)	$ (1,020,060)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Derivative expense	731,500
Stock-based compensation	837,107	326,078
Depreciation and amortization	60,665	285,130
Amortization of debt discount	148,284
Intangible impairment	15,577
Loss on debt extinguishment		81,738
Gain on debt restructuring	(516)
Gain on sale of asset	(482)	(450)
Changes in Operating Assets and Liabilities
Increase in prepaid expenses	(45,184)	(4,779)
Increase in accounts receivable	(1,250)
Interest accrued on notes payable - related party	5,603	3,039
Interest accrued on notes payable	636	725
Interest accrued on convertible notes payable	15,876	11,479
Decrease in accounts payable and accrued expense	(42,292)	(37,807)
Increase (decrease) in accrued expenses - related party	(35,821)	66,455
Net Cash Used In Operating Activities	(472,307)	(288,002)
CASH FLOWS FROM INVESTING ACTIVITIES
Increase in investments		(1,500)
Sale of equipment	482
Purchase of equipment	(81,874)
Increase in patents and trademarks	(26,599)	(24,987)
Net Cash Used in Investing Activities	(107,991)	(26,487)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from stock and warrants sale	368,500	100,000
Proceeds from PPP note payable	38,665
Proceeds from notes payable	27,500
Proceeds from convertible notes	322,500	280,000
Repayments of convertible notes	(13,962)	(11,479)
Repayments of notes payable	(244)	(19,556)
Repayments of notes payable - related party	(7,500)	(20,700)
Net Cash Provided by Financing Activities	735,459	328,265
Net Increase in Cash	155,161	13,776
Cash and Restricted Cash at Beginning of Period	10,582	6,460
Cash at End of Period	165,743	20,236
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash Paid During The Period For: Interest	26,623	15,437
Cash Paid During The Period For: Stock granted for debt conversion	25,383	455,965
SUPPLEMENTAL DISCLOSURE ON NON-CASH FINANCING AND INVESTING ACTIVITIES
Derivative treated as debt discount	352,941
Note payable - related party granted for release of claim to accrued salary	195,000
Notes payable - related party converted into common stock	$ 25,382

Summary of Significant Accounti

Summary of Significant Accounting Policies and Organization	6 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies and Organization	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Organization and Description The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota. (B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. In October 2020, the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that as of the date of this 10-Q filing has not been made effective; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures, which are included in annual financial statements, have been omitted pursuant to these rules and regulations. We believe the disclosures made in these interim unaudited financial statements are adequate to make the information not misleading. Although these interim financial statements at September 30, 2020 and for the six months ended September 30, 2020 and 2019 are unaudited, in the opinion of our management, such statements include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position, results of operations and cash flows for the periods presented. The results for the six months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ended March 31, 2021 or for any future period. These unaudited interim financial statements should be read and considered in conjunction with our audited financial statements and the notes thereto for the year ended March 31, 2020, included in our annual report on Form 10-K filed with the SEC on June 29, 2020. (C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations. All intercompany accounts have been eliminated upon consolidation. (D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, estimate of fair value of lease liabilities and related right of use asset, valuation of deferred tax assets and valuation of in-kind contribution of services and interest. (E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. At September 30, 2020, the Company had $165,743 in cash and no cash equivalents. At March 31, 2020, the Company had $10,582 in cash and restricted cash and no cash equivalents. (F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed limits insured by the Federal Deposit Insurance Corporation (FDIC). At September 30, 2020, cash did not exceed the FDIC uninsured balances and management believes the Company is not exposed to any significant credit risk on cash. (G) Property & Equipment Property and equipment are recorded at cost less accumulated depreciation. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after taking into account their respective estimated residual values) over the asset’s estimated useful life of (3) years for equipment, (5) years for automobile, and (7) years for furniture and fixtures. (H) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of a useful life of 60 months or the life of the patent. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. (I) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 5,727,610 warrants outstanding as of September 30, 2020 with varying exercise prices ranging from $.30 to $2.22/share. The weighted average exercise price for these warrants is $.50/share. These warrants are excluded from the weighted average number of shares because they are considered anti-dilutive. The Company had 3,764,912 warrants outstanding as of September 30, 2019, with varying exercise prices ranging from $3.89 to $.33/share. The weighted average exercise price for these warrants was $.55/share. These warrants are excluded from the weighted average number of shares because they are considered antidilutive. The Company uses the guidance in ASC 260 to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be antidilutive. At September 30, 2020 and 2019, the Company had $280,000 in convertible notes principal and $-0- in interest outstanding; these notes mature in our fiscal quarter ended June 30, 2021. If converted, the $280,000 in outstanding principal and $-0- in accrued interest would convert into 388,889 shares of common stock at a rate of $.72 per share. Also at September 30, 2020, the Company had a 15% OID convertible note outstanding in the principal amount of $352,941 ($-0- at September 30, 2019) that had $12,868 ($-0- at September 30, 2019) in accrued interest to yield an outstanding balance of $365,809 that is convertible into shares at a rate of $.28/share into 1,306,461 shares of common stock on or after December 15, 2020. See Note 8 to these financial statements for more information on the convertible notes discussed in this paragraph. (J) Revenue Recognition The Company recognizes revenue on arrangements in accordance with FASB ASC No. 606, “Revenue From Contracts With Customers.” Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company adopted the guidance on April 1, 2018 using the cumulative catch-up transition method. This change in accounting did not have any material effect on the Company’s financial statements. The Company recognizes revenue related to our sales of Kush product to veterinarians when we have received an order and shipped the Kush product. (K) Research and Development The Company expenses research and development costs as incurred. (L) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements,” The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of investments – equity securities receivable, notes payable and accrued interest, notes payable and accrued interest - related party, and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of September 30, 2020 and March 31, 2020, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company measured its investments – equity securities receivable at fair value at September 30, 2020, and March 31, 2020, see Note 4 to the financial statements included in this Form 10-Q. The Company accounts for derivative instruments in accordance with Accounting Standards Codification 815, Derivatives and Hedging (“ASC 815”), which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities. ASC 815 requires that an entity recognize all derivatives as either assets or liabilities in the balance sheet and measure those instruments at fair value. If certain conditions are met, a derivative may be specifically designated as a hedge, the objective of which is to match the timing of gain or loss recognition on the hedging derivative with the recognition of (i) the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk or (ii) the earnings effect of the hedged forecasted transaction. For a derivative not designated as a hedging instrument, the gain or loss is recognized in income in the period of change. (M) Stock-Based Compensation – Employees and Non-Employees Equity Instruments Issued to Employees and Non-Employees for Acquiring Goods or Services On June 20, 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments to nonemployees (for example, service providers, external legal counsel, suppliers, etc.). Under the new standard, companies will no longer be required to value non-employee awards differently from employee awards. Meaning that companies will value all equity classified awards at their grant-date under ASC 718 and forgo revaluing the award after this date. In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor's own operations by issuing share-based payment awards. The Company accounts for employee stock-based compensation the same as non-employee stock-based compensation. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. (N) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. As required by ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company applied ASC Topic 740 to all tax positions for which the statute of limitations remained open. As a result of the implementation of ASC Topic 740, the Company did not recognize any change in the liability for unrecognized tax benefits. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses. (O) Inventory Inventories are recorded in accordance with ASC 330 and are stated at the lower of cost and net realizable value. We account for inventories using the first in first out (FIFO) methodology and capitalize costs on a project basis as they occur. The current marketed shelf life of our Kush inventory is 3 years. However, management reserves the right to review and adjust this as appropriate. (P) Recently Issued and Adopted Accounting Pronouncements In January 2017, the FASB issued ASU No. 2017-04, “Intangibles and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates the requirement to calculate the implied fair value of goodwill, but rather requires an entity to record an impairment charge based on the excess of a reporting unit’s carrying value over its fair value. This amendment is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We adopted this ASU on April 1, 2020 and it did not have a material effect on our consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements on fair value measurements in Topic 820. The ASU is effective for the Registrants for fiscal years beginning after December 15, 2019, and interim periods therein. The Company adopted this ASU on April 1, 2020 and it did not have a material impact on the financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Going Concern

Going Concern	6 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 - GOING CONCERN The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company incurred net losses of $2,162,010 for the six-month period ended September 30, 2020 and had net cash used in operating activities of $472,307 for the same period. Additionally, the Company has an accumulated deficit of $56,750,655, working capital deficit of $1,970,330, and a stockholders’ deficit of $1,927,691 at September 30, 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months after the date of issuance on these consolidated financial statements. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to achieve a level of profitability and/or to obtain adequate financing through the issuance of debt or equity in order to finance its operations. Management intends to raise additional funds through a private placement or public offering of its equity securities; this is evidenced by the filing of Form S-1 with the Securities and Exchange Commission as identified in this Form 10-Q’s Note 15. Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern. While the Company believes in its viability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and raise additional funds. COVID-19 has had an impact on the global economy, which directly or indirectly may have an impact on our ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Lease and Commitments

Lease and Commitments	6 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Lease and Commitments	NOTE 3 – LEASE AND COMMITMENTS Rent expense for the three-month periods ended September 30, 2020 and September 30, 2019 were $13,568 and $13,434, respectively. Rent expense for the six-month periods ended September 30, 2020 and September 30, 2019 were $27,136 and $24,245, respectively. The Company entered into an eighty-four-month lease for 3,577 square feet of newly constructed office, laboratory and warehouse space located in Edina, Minnesota on May 3, 2017. The Company resided in the facility starting in November of 2017. The base rent started as $2,078 per month with 2% increases annually and the Company is responsible for its proportional share of common space expenses, property taxes, and building insurance. The base rent as of September 30, 2020 is $2,162. This lease is terminable by the landlord if damage causes the property to no longer be utilized as an integrated whole and by the Company if damage causes the facility to be unusable for a period of 45 days. The Company entered into a lease amendment whereby the lease term was extended through November of 2026 in exchange for a loan of $42,500 and a grant of $7,500 as a tenant improvement allowance, which has been recorded to accrued expenses and will be amortized over the remainder of the lease term. Through the balance sheet date, the Company has received $42,500 in loan proceeds and the full tenant improvement allowance amount of $7,500. The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of September 30, 2020: Year Ended March 31, 2021 $ 13,142 2022 26,634 2023 27,167 2024 27,710 2025 28,265 Thereafter 48,304 $ 171,223 Less: Amount representing interest (327 ) Present value of lease liabilities $ 170,896 In compliance with ASC 842 the Company adopted new guidance in relation to lease accounting on April 1, 2019 whereby we recognized operating lease right-to-use assets and corresponding and equal operating lease liabilities for the lease of our facility in Edina, MN. As of September 30, 2020, planned future base rent lease payments total $171,223, which has been discounted to $170,896 using the 52-week treasury bill coupon equivalent discount rate of 0.12% and a present value model. As of September 30, 2020, the Company only had one operating lease so that the remaining lease term and weighted average discount rate are approximately 6 years and 0.12%, respectively. September 30, 2020 Present value of future base rent lease payments $ 170,896 Base rent payments included in prepaid expenses - Present value of future base rent lease payments – net $ 170,896 As of September 30, 2020, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: September 30, 2020 Operating lease right-of-use asset $ 170,896 Total operating lease assets 170,896 Operating lease current liability 26,363 Operating lease other liability 144,533 Total operating lease liabilities $ 170,896 Pursuant to a lease wherein our subsidiary, Gel-Del Technologies, Inc., was the lessee until the lease’s termination in 2017, the Company has recorded approximately $330,000 as a potential payable to the lessor as of September 30, 2020; this amount is included in accounts payable.

Investments - Equity Securities

Investments - Equity Securities	6 Months Ended
	Sep. 30, 2020
Equity Method Investments and Joint Ventures [Abstract]
Investments - Equity Securities	NOTE 4 – INVESTMENTS – EQUITY SECURITIES On June 28, 2019, the Company entered into a purchase agreement with a third-party to purchase 1,500,000 shares of Emerald Organic Products, Inc. (OTC Pink: “EMOR”) common stock for consideration of $1,500. The Company applied guidance from ASU No. 2016-01 Financial Instruments – Overall – Recognition and Measurement of Financial Assets and Financial Liabilities and ASC 820 to arrive at a fair value at September 30, 2019 of $1,500. The Company took into account many factors when determining the stock’s fair value including, but not limited to, the nature and duration of the restriction on the stock, the extent to which potential buyers would be limited by the restriction, and qualitative and quantitative factors specific to both the instrument and the issuer and risk of non-performance.

Prepaid Expenses

Prepaid Expenses	6 Months Ended
	Sep. 30, 2020
Prepaid Expenses
Prepaid Expenses	NOTE 5 – PREPAID EXPENSES At September 30, 2020 and March 31, 2020, the Company had $177,207 and $132,023 in prepaid expenses, respectively. At September 30, 2020 the total prepaids amount of $177,207 was made up primarily of $132,403 in prepaid expenses – short term and $44,804 in prepaid expenses (net of current). Of the $132,403 classified as prepaid expenses – short term, approximately $80,000 is made up of advertising and marketing services yet to be performed. The $44,804 classified as prepaid expenses (net of current) is entirely made up of costs incurred related to our S-1 filing with the Securities and Exchange Commission and will be recorded as a reduction of proceeds should we be successful in raising capital through this S-1 offering.

Property and Equipment

Property and Equipment	6 Months Ended
	Sep. 30, 2020
Property and Equipment:
Property and Equipment	NOTE 6 – PROPERTY AND EQUIPMENT The components of property and equipment were as follows: September 30, 2020 March 31, 2020 Leasehold improvements $ 152,392 $ 98,706 Furniture and office equipment 10,130 10,130 Production equipment 115,661 87,473 R&D equipment 25,184 25,184 Total, at cost 303,367 221,493 Accumulated depreciation (125,548 ) (111,586 ) Total, net $ 177,819 $ 109,907 During the three months ended September 30, 2020 and 2019, depreciation expense was $7,474 and $3,442, respectively. During the six months ended September 30, 2020 and 2019, depreciation expense was $13,963 and $10,423, respectively.

Intangible Assets

Intangible Assets	6 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	NOTE 7 – INTANGIBLE ASSETS The components of intangible assets, all of which are finite-lived, were as follows: September 30, 2020 March 31, 2020 Patents $ 3,832,661 $ 3,822,542 Trademarks 25,527 25,023 Total, at cost 3,858,188 3,847,565 Accumulated Amortization (3,835,656 ) (3,788,954 ) Total, net $ 22,532 $ 58,611 During the three-month periods ended September 30, 2020 and 2019, amortization expense was $1,385 and $137,598, respectively. During the six-month periods ended September 30, 2020 and 2019, amortization expense was $46,702 and $274,707, respectively.

Convertible Notes and Notes Pay

Convertible Notes and Notes Payable	6 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Convertible Notes and Notes Payable	NOTE 8 – CONVERTIBLE NOTES AND NOTES PAYABLE At September 30, 2020, the Company is obligated for $296,801 in notes payable and notes payable – related parties and $437,180 in convertible notes payable and accrued interest, net of debt discount. At March 31, 2020, the Company is obligated for $76,350 in notes payable and $286,981 in convertible notes payable. September 30, 2020 March 31, 2020 Notes Payable Convertible Notes Payable Notes Payable Convertible Notes Payable 1. Third Parties – Principal $ 42,500 $ 632,941 $ 15,000 $ 280,000 Third Parties – Unamortized Debt Discount - (215,686 ) - - Third Parties – Interest 325 19,925 95 6,981 Third Parties – Total 42,825 437,180 15,095 286,981 2. Related Parties – Principal 252,142 - 59,642 - Related Parties – Interest 1,834 - 1,613 - Related Parties – Total 253,976 - 61,255 - Total $ 296,801 $ 437,180 $ 76,350 $ 286,981 At September 30, 2020, the Company is obligated for one convertible note payable held by RedDiamond Partners, LLC (“RDCN”); the Company entered into the RDCN on June 15, 2020, whereby the note is convertible on or after January 15, 2021 and before maturity on March 15, 2021 at a rate of $.28/share. The RDCN was issued in the principal amount of $352,941 with $52,941 being made up of a 15% Original Issue Discount (“OID”) and includes a conversion feature. However, this conversion feature’s exercise contingency can only be utilized if triggered by the occurrence of an Event of Default, which includes events that are outside the control of the Company (i.e. not based solely on the market for the Company’s stock or the Company’s own operations). Additionally, the RDCN accrues interest at a rate of 12.5% per annum, calculated on a 360-day-per-year-basis. At September 30, 2020, the Company owed $365,808 in outstanding balance whereby $352,941 was made up of principal and $12,867 was made up of accrued interest. This RDCN was issued alongside a warrant for purchase of 557,143 shares of Company common stock (“RDCN Warrants”) with a relative value of $91,500; see Note 14 for more information on these RDCN Warrants. Upon inception, the outstanding principal balance of the RDCN was reduced to $-0- by various discounts on the debt totaling ($352,941) as follows: i) the RDCN Warrants generated a discount on the debt of ($91,500) based on the relative value of the same; ii) $2,500 in investor legal costs was treated as a discount on the debt of ($2,500) since this was paid by the Company; iii) $52,941 of OID was treated as a discount on the debt of ($52,941); iv) a discount of ($206,000) was taken due to the conversion option being treated as a derivative. As of September 30, 2020, the Company had ($215,686) ($-0- at March 31, 2020) in unamortized debt discount remaining. In evaluating the various instruments and their components within this transaction (including issuance of the RDCN and RDCN Warrants) for treatment as a derivative and the respective accounting treatment of the same, the Company referenced ASC 470 and ASC 815 in conjunction with interpretive guidance. For the three and six months ended September 30, 2020, the Company amortized a pro-rata portion of the discount on the debt on a straight-line basis to interest expense in the amounts of $117,647 and $137,255, respectively. In conjunction with the RDCN and RDCN Warrants issuances, the Company also paid $30,000 and issued 75,000 warrants (“Think Warrants”) valued at $31,500 using the Black-Scholes model to Think Equity for soliciting the RedDiamond Partners, LLC transaction; see Note 14 for more information on these warrants. The total issuance costs paid to Think Equity of $61,500 of cash and warrants, which the Company recorded the relative value (as noted in Note 14) of $52,399 to expense since no further discount was available to be taken on the debt. At September 30, 2020 and March 31, 2020, the Company is/was obligated for several convertible notes payable held by accredited investors (“Accredited Investor Convertible Notes” or “AICN” or “AICNs”). At September 30, 2020 the total outstanding balance of these AICNs of $287,058 was made up of $280,000 in principal and $7,058 in accrued interest. At March 31, 2020, the total outstanding balance of these AICNs of $286,981 was made up of $280,000 in principal and $6,981 in accrued interest. The Company entered into these AICNs during the quarter ended June 30, 2019. All of these AICNs mature during the quarter ended June 30, 2021, two years from their inception dates. These AICNs accrue interest at a rate of 10% annually. Accrued interest is due and payable each calendar quarter in cash. During the three and six months ended September 30, 2020, the Company paid out $-0- and $13,962, respectively, in accrued interest to these convertible note holders. During the three and six months ended September 30, 2019, the Company paid out $6,118 and $11,479, respectively, in accrued interest to these convertible note holders. These AICNs automatically convert into shares of common stock at a rate of $.72 per share at the earlier of the maturity date or an uplist to a national securities exchange (e.g. NASDAQ or New York Stock Exchange) provided that the Company’s stock price is at least $.87 at the time of the uplist. The AICN note holders have the right to convert their outstanding principal and interest into shares of the Company’s common stock at any time during their note’s term at $.72 per share. No AICN note holders have converted their notes through the date of this report. As of September 30, 2020 and March 31, 2020, these AICNs included a beneficial conversion feature with an aggregate value of $30,154.

Derivative Liability

Derivative Liability	6 Months Ended
	Sep. 30, 2020
Derivative Liability [Abstract]
Derivative Liability	NOTE 9 – DERIVATIVE LIABILITY The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operation as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. The Company used the following assumptions for determining the fair value of the conversion feature in the RDCN referenced in Note 8 to these financial statements, under the binomial pricing model with Monte Carlo simulations at June 15, 2020 and September 30, 2020, the issuance and balance sheet dates, respectively: June 15, 2020 September 30, 2020 Stock price on valuation date $ .42 $ .80 Conversion price $ .28 $ .28 Days to maturity 273 166 Weighted-average volatility* 367 % 327 % Risk-free rate .18 % .12 % The initial valuation of $526,800 at June 15, 2020, generated a discount on the debt of $206,000, which net the convertible note liability to $-0- and forced a recognition of derivative expense of $320,800 and a corresponding offset to derivative liability of $526,800. At September 30, 2020, the Company revalued the derivative liability to $937,500. For the three months ended September 30, 2020 and 2019, the Company recognized $389,300 and $-0- to derivative expense, respectively. For the six months ended September 30, 2020 and 2019, the Company recognized $731,500 and $-0- to derivative expense and derivative liability, respectively. The Company recorded derivative liability transactions during the six-month period ended September 30, 2020 as follows: Six Months Ended September 30, 2020 Convertible note embedded derivative liability Balance at March 31, 2020 $ -0- Initial recognition of derivative liability 526,800 Change in fair value 21,400 Balance at June 30, 2020 $ 548,200 Change in fair value 389,300 Balance at September 30, 2020 $ 937,500

Convertible Notes and Notes P_2

Convertible Notes and Notes Payable - Related Party	6 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Convertible Notes and Notes Payable - Related Party	NOTE 10 – CONVERTIBLE NOTES AND NOTES PAYABLE – RELATED PARTY At September 30, 2020 and March 31, 2020, the Company was obligated for related party notes payable and accrued interest in the total amount of $253,976 and $61,255, respectively. Effective September 1, 2020, the Company entered into two debt settlement agreements with David B. Masters, a director of the Company, pursuant to an Amendment to Promissory Note and a Promissory Note. The Amendment to Promissory Note extends, for up to an additional two years and under the same terms as originally entered into, the original promissory notes which were issued by Gel-Del Technologies, Inc., a wholly owned subsidiary of the Company, to Dr. Masters. Because this Amendment to Promissory Note simply extended the term over which the Company is required to pay back the outstanding balance this change has been treated as a debt modification. The outstanding principal of $59,642 and interest balance of $6,058 of the original promissory notes was $65,700 at the time of execution of the Amendment to Promissory Note; the terms of this Amendment to Promissory Note are interest accrual at a rate of 8% on an annual basis or 20% if the note is in default. The Amendment to Promissory Note requires monthly payments of $3,100 and a maturity date of June 30, 2022 provided however that if the Company shall achieve $1,500,000 in equity sales or achieve gross product sales of $1,500,000, the Company must pay the outstanding balance at that time. The Promissory Note was entered into with an effective date of September 1, 2020 in a principal amount of $195,000, which represented David Masters’ release of any claim to the $195,000 in past accrued salary he was owed, it accrues interest at a rate of 3% per annum, has a maturity date of August 31, 2022, and requires payments of $4,000 per month beginning when the Company’s sale of products reach $3,500,000. The reclassification of the $195,000 was treated as a debt modification. A Settlement and General Release (“ Settlement Agreement At September 30, 2020, the Company was obligated for principal and accrued interest in the amounts of $192,500 and $417, respectively, related to the Promissory Note and $59,642 and $1,417, respectively, related to the Amendment to Promissory Note. At September 30, 2020 and March 31, 2020, the Company was not obligated for any related party convertible notes payable principal and accrued interest. However, the Company entered into notes payable with three directors on May 14, 2020, in the aggregate principal amount of $25,000. The notes with these three directors accrued interest at a rate of 6% annually, yielding a total amount of accrued interest of $382 at August 14, 2020, the maturity date, and on that date the total outstanding balance of $25,382 was converted at $.2538 per share into 100,010 shares of common stock valued at $25,383 as identified in Note 14.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	6 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 11 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES At September 30, 2020 and March 31, 2020, the Company is obligated to pay $751,366 and $794,057, respectively, in accounts payable and accrued expenses. Of the total at September 30, 2020, $517,278 is made up of accounts payable, while the $234,088 in accrued expenses is made up of a tenant improvement allowance of $7,500 and $226,588 is made up of past employee’s accrued salaries and related payroll taxes payable. Of the total at March 31, 2020 of $794,057, $556,653 is made up of accounts payable, while the $237,404 in accrued expenses is made up of past employee’s accrued salaries and related payroll taxes payable. The potential payroll taxes owed are not due until the accrued compensation has been paid. Since the Company has not paid these accrued wages, the Company has appropriately left the potential payroll taxes associated with these accrued wages unpaid. The Company has established an accrued liability for the potential taxes of approximately $15,209 and $22,025 at September 30, 2020 and March 31, 2020, respectively.

PPP Loan

PPP Loan	6 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
PPP Loan	NOTE 12 – PPP LOAN On May 1, 2020, the Company received $38,665 in loan proceeds pursuant to the Paycheck Protection Program enacted by the 2020 US Federal government Coronavirus Aid, Relief, and Economic Security Act. At September 30, 2020, the Company was obligated for the outstanding balance of $38,827, made up of $38,665 in principal and $162 in accrued interest. The principal and accrued interest may be forgivable and the Company has applied for forgiveness. The loan accrues interest at a rate of 1% per annum and matures on May 1, 2022; if not forgiven prior to December 1, 2020, the Company is required to pay monthly installments toward principal and interest until the note is paid in full.

Accrued Expenses - Related Part

Accrued Expenses - Related Party	6 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Accrued Expenses - Related Party	NOTE 13 – ACCRUED EXPENSES – RELATED PARTY At September 30, 2020, the Company is obligated to pay $21,270 in accrued expenses due to related parties. The total amount is made up of accounts payable to related parties. During the quarter ended September 30, 2020, David Masters signed a settlement and general release giving up any right to his $195,000 in accrued salary – related party. In exchange for this settlement and general release, the Company granted David Masters a note with a principal amount of $195,000, which is described further in this Form 10-Q’s Note 10. At March 31, 2020, the Company was obligated to pay $252,607 in accrued expenses due to related parties. Of the total, $38,954 was made up of accounts payable, while $213,653 is made up of accrued salaries and potential payroll taxes payable.

Common Stock and Warrants

Common Stock and Warrants	6 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Common Stock and Warrants	NOTE 14 - COMMON STOCK AND WARRANTS On October 23, 2020, the Company approved and declared a reverse stock split of all its outstanding common stock at a ratio of 1-for-4 shares; this reverse stock split has not yet been made effective. Equity Incentive Plan On July 10, 2020, our Board of Directors unanimously approved the PetVivo Holdings, Inc “2020 Equity Incentive Plan” (the “2020 Plan”), subject to approval by our stockholders at the Regular Meeting of Stockholders held on September 22, 2020, when it was approved by our stockholders and became effective. The number of shares of our common stock available and that may be issued as awards under the 2020 Plan is 4,000,000 shares. Unless sooner terminated by the Board, the 2020 Plan will terminate at midnight on July 10, 2030. Eligible Participants Administration Shares Available for Awards ● the maximum aggregate number of shares of Common Stock granted as an Award to any Non-Employee Director in any one Plan Year will be 100,000 shares; provided that such limit will not apply to any election of a Non-Employee Director to receive shares of Common Stock in lieu of all or a portion of any annual Board, committee, chair or other retainer, or any meeting fees otherwise payable in cash. Types of Awards The 2020 Plan permits the following types of awards: stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards, other stock-based awards, and dividend equivalents. As of September 30, 2020, the Company has not awarded any shares pursuant to the 2020 Plan. Common Stock During the six-month period ended September 30, 2020 the Company issued 466,086 shares of common stock as follows: i) 120,000 shares valued at $40,680 and recorded in Stock-based compensation to a service provider for video marketing services over a 6-month term; ii) 80,000 shares with a relative value of $34,709 pursuant to a purchase of 80,000 units whereby a unit is made up of 1 share of common stock and ½ warrant. The value of $34,709 along with the relative value of the warrants associated with this transaction of $17,291 ($52,000 total) was recorded during the quarter ended March 31, 2020 to Common Stock Subscribed and moved to Additional Paid in Capital and Capital Stock upon receipt of funds and issuance of shares of common stock during the quarter ended June 30, 2020; iii) 50,000 shares valued at $22,000 on July 1, 2020 to two service providers as follows: a) 40,000 to a marketing and investor relations service provider valued at $17,600; and b) 10,000 to a legal service provider valued at $4,400; iv) 61,027 shares valued at $12,053 on July 24, 2020 to one warrant holder whereby this warrant holder converted on a cashless basis 100,000 warrants into 61,027 shares of common stock and the warrant had an exercise price of $.30 per share; v) 904,288 shares during August and September of 2020 in exchange for $316,500 in cash to four accredited investors; vi) 649,007 shares valued at $486,755 to directors and officers on September 14, 2020 as bonuses for work over the past two years as follows: a. 134,479 to John Lai b. 104,867 to John Carruth c. 91,976 to John Dolan d. 43,157 to Gregory Cash e. 42,848 to David Deming f. 42,509 to Robert Rudelius g. 42,197 to Randy Meyer h. 37,205 to Jim Martin i. 37,197 to Scott Johnson j. 36,835 to Joseph Jasper k. 35,737 to David Masters vii) 100,010 shares valued at $25,383 to three directors on August 14, 2020, pursuant to their conversions of notes in the total outstanding balance amount of $25,382 made up of $25,000 in principal and $382 in accrued interest; these notes had a set conversion price of $.2538 per share. During the six months ended September 30, 2019, the Company issued 1,763,872 shares of common stock as follows: i) 348,000 shares to John Lai pursuant to a Settlement Agreement whereby Mr. Lai agreed to release the Company of all claims through the date of the agreement, September 11, 2019, including accrued compensation he had earned in the amount of $116,000 and hold the shares for a period of at least 3 years; ii) 575,808 shares to Randall Meyer pursuant to a Settlement Agreement whereby Mr. Meyer agreed to release the Company of all claims through the date of the agreement, September 11, 2019, including accrued compensation he had earned in the amount of $191,936 and hold the shares for a period of at least 3 years; iii) 204,000 shares to John Dolan pursuant to a Settlement Agreement whereby Mr. Dolan agreed to release the Company of all claims through the date of the agreement, September 11, 2019, including accrued compensation he had earned in the amount of $68,000 and hold the shares for a period of at least 3 years; and iv) 168,060 shares to a former employee pursuant to a Settlement Agreement dated August 29, 2019, whereby this individual agreed to release the Company of all claims, including compensation earned in the amount of $80,029; and v) 108,000 shares valued at $120,000 to a service provider for production services provided during the one-year period ended July 13, 2019 and recognized over that period on a pro-rata basis; and vi) 360,000 shares on September 13, 2019, to one shareholder that the Company sold in exchange for $100,000; vii) 270,000 shares valued at $102,000 to a service provider on September 18, 2019, in exchange for 12 months of video production and marketing services. John Lai (CEO, President & Director), Randall Meyer (Director), and John Dolan (Secretary & Director) are all related parties, and the reduction of $375,936 was included in Accrued Expenses – Related Party. The settlement of $80,029 for a former employee’s accrued salary was accounted for as a reduction of Accounts Payable and Accrued Expenses. A loss on extinguishment of debt was recorded in the amount of $81,738 related to these transactions as indicated in Roman numerals i-iv above. Warrants During the six-month period ended September 30, 2020, the Company granted warrants to purchase a total of 240,627 shares of common stock valued at $443,108, including: i) warrants for 40,000 shares, valued at $17,291 using the Black-Scholes model, to one investor, whereby the value was recorded during the quarter ended March 31, 2020 to Common Stock Subscribed and moved to Additional Paid in Capital upon receipt of funds and issuance of warrants on April 6, 2020, and further whereas the warrants vested immediately upon issuance and are exercisable at $4.00 per share for 3 years from the grant date of April 6, 2020; ii) warrants for 90,000 shares, valued at $28,964 using the Black-Scholes model, to John Lai, whereby the value was recorded to Stock-based compensation and the warrants vest upon the Company raising $10,000,000 or more through an S-1 offering as long as that occurs prior to October 31, 2020; if these warrants vest they will be exercisable for a period of 5-years at $.35 per share; iii) warrants for 557,143 shares (RDCN Warrants), valued at $234,000 using the Black-Scholes model, to RedDiamond Partners, LLC, whereby the relative value of $91,500 was recorded to Warrants issued in conjunction with convertible debt on the statement of equity; the warrants have a cashless warrant exercise feature, are exercisable at $.35 per share for a term of five years from the date of the grant of June 15, 2020 when the Company entered into a securities purchase agreement and issued a convertible note as outlined in Note 8 and vested immediately; iv) warrants for 75,000 shares (Think Warrants), valued at $31,500 using the Black-Scholes model, whereby the relative value of the warrants was recorded to Stock-based compensation, whereas the warrants are exercisable for 5 years from the date of the grant of June 15, 2020 at an exercise price of $.35 per share. The Think Warrants were issued to Think Equity as a placement fee for soliciting the RedDiamond transaction as described in Roman numeral iii above and Note 8 to these financial statements and vested immediately; v) warrants for 27,237 shares on June 30, 2020, valued at $11,984 using the Black-Scholes model, whereby the value of the warrants was recorded to Stock-based compensation, whereas the warrants are exercisable for 5 years from the date of the grant at $.40 per share to various directors of the Company for services on various committees and vested immediately; vi) warrants for 29,762 shares on June 30, 2020, valued at $13,095 using the Black-Scholes model, whereby the value of the warrants was recorded to Stock-based compensation on the statement of equity, whereas the warrants are exercisable for 5 years from the date of the grant at $.40 per share to John Lai and vested immediately; vii) warrants for 8,349 shares on June 30, 2020, valued at $3,674 using the Black-Scholes model, whereby the value of the warrants was recorded to Stock-based compensation on the statement of equity, whereas the warrants are exercisable for 5 years from the date of the grant at $.40 per share to a service provider for various production and manufacturing consulting services and vested immediately; viii) warrants for 7,500 shares on July 1, 2020, valued at $3,300 using the Black-Scholes model, whereby the value of the warrants was recorded to Stock-based compensation on the statement of equity and whereas the warrants vest monthly in equal installments for two months from the date of the grant and are exercisable for 5 years from the date of the grant at $.40 per share to Joseph Jasper for board service; ix) warrants for 7,500 shares on July 1, 2020, valued at $3,300 using the Black-Scholes model, whereby the value of the warrants was recorded to Stock-based compensation on the statement of equity and whereas the warrants vest monthly in equal installments for two months from the date of the grant and are exercisable for 5 years from the date of the grant at $.40 per share to Robert Rudelius for board service; x) warrants for 120,000 shares on September 1, 2020, valued at $96,000 using the Black-Scholes model, whereby the value of the warrants is recorded to Stock-based compensation on the statement of equity in equal monthly installments as they vest in equal monthly installments for four months from the date of the grant and are exercisable for 5 years from the date of the grant at $.35 per share to David Masters for production and manufacturing consulting services. These warrants’ values were arrived at by using the Black-Scholes valuation model with the following assumptions: i) an expected volatility of the Company’s shares on the date of the grants of between approximately 350% and 433%, which were arrived at by taking the number of trading days during the year ended on the date of the grant multiplied by the standard deviation of the percentage change in the closing market price on a day-by-day basis; and ii) risk-free rates identical to the U.S. Treasury 3-year and 5-year treasury bill rates on the date of the grants between 0.29% and 1.16%. During the six months ended September 30, 2019, the Company granted warrants to purchase a total of 270,000 shares of common stock including: i) warrants for 270,000 shares, valued at $119,954, to three new Directors, Messrs. Scott Johnson, Gregory Cash, and James Martin, with 135,000 vested immediately and 135,000 vesting quarterly between August 2020 and May 2021, and exercisable over a five-year term at $.33/share. These warrants’ values were arrived at by using the Black-Scholes valuation model with the following assumptions: i) an expected volatility of the Company’s shares on the date of the grants of approximately 313%, which was arrived at by taking the number of trading days during the year ended on the date of the grant multiplied by the standard deviation of the percentage change in the closing market price on a day-by-day basis; and ii) a risk-free rate identical to the U.S. Treasury 13-week treasury bill rate on the date of the grants of 2.30% During the six months ended September 30, 2019, the Company cancelled 324,000 warrants to purchase a total of 324,000 shares of common stock including: i) warrants for 270,000 shares, valued at $300,770 using the Black-Scholes model, $117,144 in expense of which had yet to be taken at the time of cancellation were cancelled pursuant to the terms of such warrants dictating cancellation upon the two-month anniversary of a cease of service; and ii) warrants for 54,000 shares that were never originally valued, were to be vested upon billing from service providers, and were cancelled due to termination of these relationships. A summary of warrant activity for the year ending March 31, 2020 and six-month period ending September 30, 2020 is as follows: Number of Weighted- Warrants Weighted- Outstanding, March 31, 2019 3,818,919 2.20 3,035,035 0.54 Granted 1,905,700 2.07 Cashless warrant exercises (337,500 ) 1.27 Expired (90,000 ) 2.22 Canceled (396,000 ) 2.32 Outstanding, March 31, 2020 4,901,119 2.12 4,072,369 0.53 Issued in conjunction with convertible debt 632,143 0.35 Sold 40,000 1.00 Granted 290,348 0.37 Expired (36,000 ) 3.89 Cashless warrant exercises (100,000 ) 0.30 Outstanding, September 30, 2020 5,727,610 0.50 5,073,860 0.48 At September 30, 2020, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Number of Warrants Weighted- Average Exercise Price 1.20-2.00 3,122,192 0.34 4.35 3,278,442 0.33 2.01-4.00 2,145,739 0.58 2.42 1,335,739 0.60 4.01-10.00 459,679 1.23 2.01 459,679 1.23 Total 5,727,610 0.50 3.44 5,073,860 0.48 For the six-month periods ended September 30, 2020 and 2019, the total stock-based compensation on all instruments was $837,107 and $326,078, respectively. It is expected that the Company will recognize expense after September 30, 2020 related to warrants issued, outstanding, and valued using the Black Scholes pricing model as of September 30, 2020 in the amount of approximately $412,000.

Subsequent Events

Subsequent Events	6 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 15 – SUBSEQUENT EVENTS On October 15, 2020, the Company entered into a Note Conversion Agreement with David Masters whereby the parties have agreed to convert the principal amount of the Promissory Note as described in Note 10 of $192,500 and a $3,500 conversion fee into units with terms to be determined by a public offering facilitated by ThinkEquity, a division of Fordham Financial Management, Inc. On October 13, 2020, the Company filed its S-1 Registration Statement with the SEC to attempt to raise $10,000,000. On October 25, 2020, one warrant holder exercised their warrant for 54,000 shares of common stock in exchange for $30,000. On October 26, 2020, the Company entered into a note conversion agreement to convert the RDCN (as referenced in this Form 10-Q’s Note 8) in the total outstanding balance amount of $368,995 made up of $352,941 in principal and $16,054 in accrued interest into 1,054,271 shares of common stock at a rate of $.35 per share. On October 26, 2020, one warrant holder exercised their warrant for 13,500 shares of common stock in exchange for $7,500. On October 28, 2020, one warrant holder exercised their warrant for 51,429 shares of common stock in exchange for $28,571. On October 28, 2020, one warrant holder converted 27,000 warrants for common stock into 3,172 shares of common stock on a cashless basis based on an exercise and conversion price of $1.11 per share and a 10-day variable weighted average price of $1.259 per share. On October 30, 2020, John Lai converted 168,750 warrants for common stock into 129,387 shares of common stock on a cashless basis based on an exercise and conversion price of $.33 per share and a 10-day variable weighted average price of $1.429 per share. On November 4, 2020, one warrant holder exercised their warrant for 27,000 shares of common stock in exchange for $15,000. On November 5, 2020, one warrant holder exercised their warrant for 27,000 shares of common stock in exchange for $15,000. On November 5, 2020, the Company entered into an agreement with Colorado State University to conduct a study of PetVivo’s Kush product in a minimum of 16 dogs; the study is titled “Evaluation of the effect of intra-articular injection of a proprietary extracellular matrix for osteoarthritis-associated pain in dogs.”

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Organization (Policies)	6 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description	(A) Organization and Description The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota.
Basis of Presentation	(B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. In October 2020, the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that as of the date of this 10-Q filing has not been made effective; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures, which are included in annual financial statements, have been omitted pursuant to these rules and regulations. We believe the disclosures made in these interim unaudited financial statements are adequate to make the information not misleading. Although these interim financial statements at September 30, 2020 and for the six months ended September 30, 2020 and 2019 are unaudited, in the opinion of our management, such statements include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position, results of operations and cash flows for the periods presented. The results for the six months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ended March 31, 2021 or for any future period. These unaudited interim financial statements should be read and considered in conjunction with our audited financial statements and the notes thereto for the year ended March 31, 2020, included in our annual report on Form 10-K filed with the SEC on June 29, 2020.
Principles of Consolidation	(C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations. All intercompany accounts have been eliminated upon consolidation.
Use of Estimates	(D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, estimate of fair value of lease liabilities and related right of use asset, valuation of deferred tax assets and valuation of in-kind contribution of services and interest.
Cash and Cash Equivalents	(E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. At September 30, 2020, the Company had $165,743 in cash and no cash equivalents. At March 31, 2020, the Company had $10,582 in cash and restricted cash and no cash equivalents.
Concentration-Risk	(F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed limits insured by the Federal Deposit Insurance Corporation (FDIC). At September 30, 2020, cash did not exceed the FDIC uninsured balances and management believes the Company is not exposed to any significant credit risk on cash.
Property & Equipment	(G) Property & Equipment Property and equipment are recorded at cost less accumulated depreciation. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after taking into account their respective estimated residual values) over the asset’s estimated useful life of (3) years for equipment, (5) years for automobile, and (7) years for furniture and fixtures.
Patents and Trademarks	(H) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of a useful life of 60 months or the life of the patent. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired.
Loss Per Share	(I) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 5,727,610 warrants outstanding as of September 30, 2020 with varying exercise prices ranging from $.30 to $2.22/share. The weighted average exercise price for these warrants is $.50/share. These warrants are excluded from the weighted average number of shares because they are considered anti-dilutive. The Company had 3,764,912 warrants outstanding as of September 30, 2019, with varying exercise prices ranging from $3.89 to $.33/share. The weighted average exercise price for these warrants was $.55/share. These warrants are excluded from the weighted average number of shares because they are considered antidilutive. The Company uses the guidance in ASC 260 to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be antidilutive. At September 30, 2020 and 2019, the Company had $280,000 in convertible notes principal and $-0- in interest outstanding; these notes mature in our fiscal quarter ended June 30, 2021. If converted, the $280,000 in outstanding principal and $-0- in accrued interest would convert into 388,889 shares of common stock at a rate of $.72 per share. Also at September 30, 2020, the Company had a 15% OID convertible note outstanding in the principal amount of $352,941 ($-0- at September 30, 2019) that had $12,868 ($-0- at September 30, 2019) in accrued interest to yield an outstanding balance of $365,809 that is convertible into shares at a rate of $.28/share into 1,306,461 shares of common stock on or after December 15, 2020. See Note 8 to these financial statements for more information on the convertible notes discussed in this paragraph.
Revenue Recognition	(J) Revenue Recognition The Company recognizes revenue on arrangements in accordance with FASB ASC No. 606, “Revenue From Contracts With Customers.” Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company adopted the guidance on April 1, 2018 using the cumulative catch-up transition method. This change in accounting did not have any material effect on the Company’s financial statements. The Company recognizes revenue related to our sales of Kush product to veterinarians when we have received an order and shipped the Kush product.
Research and Development	(K) Research and Development The Company expenses research and development costs as incurred.
Fair Value of Financial Instruments	(L) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements,” The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of investments – equity securities receivable, notes payable and accrued interest, notes payable and accrued interest - related party, and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of September 30, 2020 and March 31, 2020, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company measured its investments – equity securities receivable at fair value at September 30, 2020, and March 31, 2020, see Note 4 to the financial statements included in this Form 10-Q. The Company accounts for derivative instruments in accordance with Accounting Standards Codification 815, Derivatives and Hedging (“ASC 815”), which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities. ASC 815 requires that an entity recognize all derivatives as either assets or liabilities in the balance sheet and measure those instruments at fair value. If certain conditions are met, a derivative may be specifically designated as a hedge, the objective of which is to match the timing of gain or loss recognition on the hedging derivative with the recognition of (i) the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk or (ii) the earnings effect of the hedged forecasted transaction. For a derivative not designated as a hedging instrument, the gain or loss is recognized in income in the period of change.
Stock-Based Compensation - Employees and Non-Employees	(M) Stock-Based Compensation – Employees and Non-Employees Equity Instruments Issued to Employees and Non-Employees for Acquiring Goods or Services On June 20, 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments to nonemployees (for example, service providers, external legal counsel, suppliers, etc.). Under the new standard, companies will no longer be required to value non-employee awards differently from employee awards. Meaning that companies will value all equity classified awards at their grant-date under ASC 718 and forgo revaluing the award after this date. In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor's own operations by issuing share-based payment awards. The Company accounts for employee stock-based compensation the same as non-employee stock-based compensation. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments.
Income Taxes	(N) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. As required by ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company applied ASC Topic 740 to all tax positions for which the statute of limitations remained open. As a result of the implementation of ASC Topic 740, the Company did not recognize any change in the liability for unrecognized tax benefits. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses.
Inventory	(O) Inventory Inventories are recorded in accordance with ASC 330 and are stated at the lower of cost and net realizable value. We account for inventories using the first in first out (FIFO) methodology and capitalize costs on a project basis as they occur. The current marketed shelf life of our Kush inventory is 3 years. However, management reserves the right to review and adjust this as appropriate.
Recently Issued and Adopted Accounting Pronouncements	(P) Recently Issued and Adopted Accounting Pronouncements In January 2017, the FASB issued ASU No. 2017-04, “Intangibles and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates the requirement to calculate the implied fair value of goodwill, but rather requires an entity to record an impairment charge based on the excess of a reporting unit’s carrying value over its fair value. This amendment is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We adopted this ASU on April 1, 2020 and it did not have a material effect on our consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements on fair value measurements in Topic 820. The ASU is effective for the Registrants for fiscal years beginning after December 15, 2019, and interim periods therein. The Company adopted this ASU on April 1, 2020 and it did not have a material impact on the financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Lease and Commitments (Tables)

Lease and Commitments (Tables)	6 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Maturity Analysis of Operating Lease Liabilities	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of September 30, 2020: Year Ended March 31, 2021 $ 13,142 2022 26,634 2023 27,167 2024 27,710 2025 28,265 Thereafter 48,304 $ 171,223 Less: Amount representing interest (327 ) Present value of lease liabilities $ 170,896
Schedule of Future Lease Payments	September 30, 2020 Present value of future base rent lease payments $ 170,896 Base rent payments included in prepaid expenses - Present value of future base rent lease payments – net $ 170,896
Schedule of Present Value of Future Lease Payments Between Current and Non-current Assets and Liabilities	As of September 30, 2020, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: September 30, 2020 Operating lease right-of-use asset $ 170,896 Total operating lease assets 170,896 Operating lease current liability 26,363 Operating lease other liability 144,533 Total operating lease liabilities $ 170,896

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Sep. 30, 2020
Property and Equipment:
Schedule of Property and Equipment	The components of property and equipment were as follows: September 30, 2020 March 31, 2020 Leasehold improvements $ 152,392 $ 98,706 Furniture and office equipment 10,130 10,130 Production equipment 115,661 87,473 R&D equipment 25,184 25,184 Total, at cost 303,367 221,493 Accumulated depreciation (125,548 ) (111,586 ) Total, net $ 177,819 $ 109,907

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The components of intangible assets, all of which are finite-lived, were as follows: September 30, 2020 March 31, 2020 Patents $ 3,832,661 $ 3,822,542 Trademarks 25,527 25,023 Total, at cost 3,858,188 3,847,565 Accumulated Amortization (3,835,656 ) (3,788,954 ) Total, net $ 22,532 $ 58,611

Convertible Notes and Notes P_3

Convertible Notes and Notes Payable (Tables)	6 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Convertible Notes and Notes Payable	At March 31, 2020, the Company is obligated for $76,350 in notes payable and $286,981 in convertible notes payable. September 30, 2020 March 31, 2020 Notes Payable Convertible Notes Payable Notes Payable Convertible Notes Payable 1. Third Parties – Principal $ 42,500 $ 632,941 $ 15,000 $ 280,000 Third Parties – Unamortized Debt Discount - (215,686 ) - - Third Parties – Interest 325 19,925 95 6,981 Third Parties – Total 42,825 437,180 15,095 286,981 2. Related Parties – Principal 252,142 - 59,642 - Related Parties – Interest 1,834 - 1,613 - Related Parties – Total 253,976 - 61,255 - Total $ 296,801 $ 437,180 $ 76,350 $ 286,981

Derivative Liability (Tables)

Derivative Liability (Tables)	6 Months Ended
	Sep. 30, 2020
Derivative Liability [Abstract]
Schedule of Derivative Liability Assumptions	The Company used the following assumptions for determining the fair value of the conversion feature in the RDCN referenced in Note 8 to these financial statements, under the binomial pricing model with Monte Carlo simulations at June 15, 2020 and September 30, 2020, the issuance and balance sheet dates, respectively: June 15, 2020 September 30, 2020 Stock price on valuation date $ .42 $ .80 Conversion price $ .28 $ .28 Days to maturity 273 166 Weighted-average volatility* 367 % 327 % Risk-free rate .18 % .12 %
Schedule of Derivative Liability	The Company recorded derivative liability transactions during the six-month period ended September 30, 2020 as follows: Six Months Ended September 30, 2020 Convertible note embedded derivative liability Balance at March 31, 2020 $ -0- Initial recognition of derivative liability 526,800 Change in fair value 21,400 Balance at June 30, 2020 $ 548,200 Change in fair value 389,300 Balance at September 30, 2020 $ 937,500

Common Stock and Warrants (Tabl

Common Stock and Warrants (Tables)	6 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Schedule of Warrant Activity	A summary of warrant activity for the year ending March 31, 2020 and six-month period ending September 30, 2020 is as follows: Number of Weighted- Warrants Weighted- Outstanding, March 31, 2019 3,818,919 2.20 3,035,035 0.54 Granted 1,905,700 2.07 Cashless warrant exercises (337,500 ) 1.27 Expired (90,000 ) 2.22 Canceled (396,000 ) 2.32 Outstanding, March 31, 2020 4,901,119 2.12 4,072,369 0.53 Issued in conjunction with convertible debt 632,143 0.35 Sold 40,000 1.00 Granted 290,348 0.37 Expired (36,000 ) 3.89 Cashless warrant exercises (100,000 ) 0.30 Outstanding, September 30, 2020 5,727,610 0.50 5,073,860 0.48
Schedule of Range of Warrant Prices	At September 30, 2020, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Number of Warrants Weighted- Average Exercise Price 1.20-2.00 3,122,192 0.34 4.35 3,278,442 0.33 2.01-4.00 2,145,739 0.58 2.42 1,335,739 0.60 4.01-10.00 459,679 1.23 2.01 459,679 1.23 Total 5,727,610 0.50 3.44 5,073,860 0.48

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Organization (Details Narrative) - USD ($)	Oct. 26, 2020	Oct. 23, 2020	May 02, 2020	Oct. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Nov. 12, 2020	Mar. 31, 2020
Reverse stock split, description		On October 23, 2020, the Company approved and declared a reverse stock split of all its outstanding common stock at a ratio of 1-for-4 shares; this reverse stock split has not yet been made effective.
Common stock, shares authorized					225,000,000			225,000,000
Cash					$ 165,743			$ 10,582
Cash equivalents
Restricted cash								10,582
Debt instrument maturity date			May 1, 2022		Apr. 30, 2020
Assets and liabilities measured at fair value
Income tax likelihood percentage					Greater than 50 percent
Inventory terms					3 years
Convertible Notes [Member]
Convertible notes outstanding					$ 280,000
Convertible notes interest outstanding					$ 0
Debt instrument maturity date					Jun. 30, 2021
Conversion of debt into common stock amount					$ 280,000
Conversion of debt into common stock shares					388,889
Conversion price per share					$ .72
OID Convertible Notes [Member]
Convertible notes outstanding					$ 352,941	$ 0
Conversion of debt into common stock amount					$ 365,809
Conversion of debt into common stock shares					1,306,461
Conversion price per share					$ .28
Accrued interest					$ 12,868	$ 0
Warrant [Member]
Warrants outstanding					5,727,610	3,764,912
Weighted average, exercise price					$ .50	$ .55
Warrant [Member] | Minimum [Member]
Warrant exercise price					.30	0.33
Warrant [Member] | Maximum [Member]
Warrant exercise price					$ 2.22	$ 3.89
Patents and Trademarks [Member]
Estimated useful life of intangible asset					60 months
Equipment [Member]
Estimated useful life of assets					3 years
Automobile [Member]
Estimated useful life of assets					5 years
Furniture and Fixtures [Member]
Estimated useful life of assets					7 years
Subsequent Event [Member]
Reverse stock split, description				The Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was effected on November 12, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000. Pursuant to this reverse stock split, each four (4) shares of PetVivo's outstanding common stock, $.001 par value per share, was combined and converted into one (1) post-split outstanding shares of common stock, $.001 par value per share
Common stock, shares authorized							250,000,000
Weighted average, exercise price				$ 5.04
Subsequent Event [Member] | OID Convertible Notes [Member]
Conversion of debt into common stock amount	$ 368,995
Accrued interest	$ 16,054

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Mar. 31, 2020	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (1,348,002)	$ (814,008)	$ (519,173)	$ (500,887)	$ (2,162,010)	$ (1,020,060)
Net cash used in operating activities					(472,307)	(288,002)
Accumulated deficit	(56,750,655)				(56,750,655)		$ (54,588,645)
Working capital	(1,970,330)				(1,970,330)
Stockholders' deficit	$ (1,927,691)	$ (1,575,434)	$ (799,095)	$ (1,154,903)	$ (1,927,691)	$ (799,095)	$ (1,036,170)	$ (844,817)

Lease and Commitments (Details

Lease and Commitments (Details Narrative)	May 03, 2017USD ($)ft²	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)Integer	Sep. 30, 2019USD ($)
Rent expense		$ 13,568	$ 13,434	$ 27,136	$ 24,245
Area of land | ft²	3,577
Base rent	$ 2,078	2,162		2,162
Annual increase in rent	0.02
Unusable period	45 days
Loan amount		42,500		42,500
Grant for lease improvements		7,500		7,500
Proceeds from loans				42,500
Tenant improvement allowance				7,500
Operating lease payment		171,223		171,223
Operating lease liability net of discount		$ 170,896		$ 170,896
Operating lease discount rate		0.12%		0.12%
Number of operating lease | Integer				1
Weighted average remaining lease term		6 years		6 years
Weighted average discount rate		0.12%		0.12%
Edina Facility [Member]
Operating lease payment		$ 171,223		$ 171,223
Gel-Del Technologies, Inc [Member]
Operating lease payment		$ 330,000		$ 330,000

Lease and Commitments - Schedul

Lease and Commitments - Schedule of Maturity Analysis of Operating Lease Liabilities (Details)	Sep. 30, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021	$ 13,142
2022	26,634
2023	27,167
2024	27,710
2025	28,265
Thereafter	48,304
Total	171,223
Less: Amount representing interest	(327)
Present value of lease liabilities	$ 170,896

Lease and Commitments - Sched_2

Lease and Commitments - Schedule of Future Lease Payments (Details)	Sep. 30, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
Present value of future base rent lease payments	$ 170,896
Base rent payments included in prepaid expenses
Present value of future base rent lease payments - net	$ 170,896

Lease and Commitments - Sched_3

Lease and Commitments - Schedule of Present Value of Future Lease Payments Between Current and Non-current Assets and Liabilities (Details) - USD ($)	Sep. 30, 2020	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use asset	$ 170,896
Total operating lease assets	170,896	$ 148,693
Operating lease current liability	26,363	$ 24,791
Operating lease other liability	144,533
Total operating lease liabilities	$ 170,896

Investments - Equity Securiti_2

Investments - Equity Securities (Details Narrative) - USD ($)	Jun. 28, 2020	Sep. 30, 2019
Fair value of investments		$ 1,500
Purchase Agreement [Member] | Emerald Organic Products Inc [Member]
Number of shares purchased for acquisition	1,500,000
Value of shares purchased for acquisition	$ 1,500

Prepaid Expenses (Details Narra

Prepaid Expenses (Details Narrative) - USD ($)	Sep. 30, 2020	Mar. 31, 2020
Prepaid Expenses	$ 177,207	$ 132,023
Prepaid expenses - short term	132,403	132,023
Prepaid expenses (net of current)	44,804
Advertising and Marketing Services [Member]
Prepaid Expenses	$ 80,000

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Property and Equipment:
Depreciation expense	$ 7,474	$ 3,442	$ 13,963	$ 10,423

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2020	Mar. 31, 2020
Total, at cost	$ 303,367	$ 221,493
Accumulated depreciation	(125,548)	(111,586)
Total, net	177,819	109,907
Leasehold Improvements [Member]
Total, at cost	152,392	98,706
Furniture and Office Equipment [Member]
Total, at cost	10,130	10,130
Production Equipment [Member]
Total, at cost	115,661	87,473
R&D Equipment [Member]
Total, at cost	$ 25,184	$ 25,184

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 1,385	$ 137,598	$ 46,702	$ 274,707

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Sep. 30, 2020	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 3,832,661	$ 3,822,542
Trademarks	25,527	25,023
Total, at cost	3,858,188	3,847,565
Accumulated Amortization	(3,835,656)	(3,788,954)
Total, net	$ 22,532	$ 58,611

Convertible Notes and Notes P_4

Convertible Notes and Notes Payable (Details Narrative) - USD ($)	May 02, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Mar. 31, 2020
Notes payable		$ 296,801		$ 296,801		$ 76,350
Notes payable - related parties		296,801		296,801
Convertible Notes payable		437,180		$ 437,180		286,981
Convertible notes maturity date	May 1, 2022			Apr. 30, 2020
Convertible notes accrued interest rate	1.00%
Debt Principal	$ 38,665
Discount on debt		117,647		$ 137,255
Unamortized Debt Discount		(215,686)		(215,686)		0
Accrued interest paid				$ 26,623	$ 15,437
Conversion price per share description				These AICNs automatically convert into shares of common stock at a rate of $.72 per share at the earlier of the maturity date or an uplist to a national securities exchange (e.g. NASDAQ or New York Stock Exchange) provided that the Company's stock price is at least $.87 at the time of the uplist. The AICN note holders have the right to convert their outstanding principal and interest into shares of the Company's common stock at any time during their note's term at $.72 per share.
15% OID Convertible Note [Member]
Accrued interest		12,867		$ 12,867
Conversion of debt into common stock amount				365,808
Convertible notes outstanding		$ 352,941		352,941
Discount on debt				(52,941)
Total Debt issuance cost				$ 61,500
Convertible Note Payable [Member]
Conversion price per share		$ .72		$ .72
Accrued interest paid		$ 0	$ 6,118	$ 13,962	$ 11,479
Stock price		$ .87		$ .87
Convertible Note Payable [Member] | Derivative [Member]
Discount on debt				$ (206,000)
Convertible Note Payable [Member] | Investor [Member]
Discount on debt				(2,500)
Convertible Note Payable [Member] | Think Equity [Member]
Discount on debt				(52,399)
Payment of convertible debt				$ 31,500
Number of Warrants issued				75,000
Accredited convertible Notes [Member]
Convertible notes maturity date				Jun. 30, 2021
Accrued interest		$ 7,058		$ 7,058		$ 6,981
Convertible notes accrued interest rate						10.00%
Conversion of debt into common stock amount				280,000		$ 280,000
Convertible notes outstanding		287,058		287,058		286,981
Beneficial conversion feature, aggregate value				30,154		$ 30,154
RedDiamond Partners, LLC [Member]
Convertible Notes payable		$ 352,941		$ 352,941
Convertible notes maturity date				Mar. 15, 2021
Conversion price per share		$ .28		$ .28
Accrued interest		$ 52,941		$ 52,941
Original issue discount percentage		15.00%		15.00%
Convertible notes accrued interest rate		12.50%		12.50%
Number of warrants purchase		557,143		557,143
Warrants purchase Amount		$ 91,500		$ 91,500
Debt Principal		$ 352,941		352,941
Discount on debt				(91,500)
Payment of convertible debt				$ 30,000

Convertible Notes and Notes P_5

Convertible Notes and Notes Payable - Schedule of Convertible Notes and Notes Payable (Details) - USD ($)	Sep. 30, 2020	May 02, 2020	Mar. 31, 2020
Debt Principal		$ 38,665
Notes Payable [Member]
Total	$ 296,801		$ 76,350
Notes Payable [Member] | Related Party [Member]
Debt Principal	252,142		59,642
Interest	1,834		1,613
Total	253,976		61,255
Notes Payable [Member] | Third parties [Member]
Debt Principal	42,500		15,000
Unamortized Debt Discount
Interest	325		95
Total	42,825		15,095
Convertible Note Payable [Member]
Total	437,180		286,981
Convertible Note Payable [Member] | Related Party [Member]
Debt Principal
Interest
Total
Convertible Note Payable [Member] | Third parties [Member]
Debt Principal	632,941		280,000
Unamortized Debt Discount	(215,686)
Interest	19,925		6,981
Total	$ 437,180		$ 286,981

Derivative Liability (Details N

Derivative Liability (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Jun. 15, 2020	Mar. 31, 2020
Derivative Liability [Abstract]
Recognition of derivative liability						$ 526,800
Discount on debt						206,000
Convertible note embeded derivative liability						$ 0
Derivative expense			320,800
Corresponding offset to derivative liability	526,800		526,800
Derivative liability	937,500		937,500		$ 548,200
Derivative expense and derivative liability	$ 389,300	$ 0	$ 731,500	$ 0

Derivative Liability - Schedule

Derivative Liability - Schedule of Derivative Liability Assumptions (Details)	Jun. 15, 2020$ / shares	Sep. 30, 2020$ / shares
Stock price on valuation date	$ .42	$ .80
Conversion price	$ .28	$ .28
Days to maturity	273 days	166 days
Weighted-average Volatility [Member]
Derivative liability measurement input	3.67	3.27
Risk-free Rate [Member]
Derivative liability measurement input	.18	0.0012

Derivative Liability - Schedu_2

Derivative Liability - Schedule of Derivative Liability (Details) - USD ($)	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020
Derivative Liability [Abstract]
Beginning balance	$ 548,200
Initial recognition of derivative liability		526,800
Change in fair value	389,300	21,400
Ending balance	$ 937,500	$ 548,200

Convertible Notes and Notes P_6

Convertible Notes and Notes Payable - Related Party (Detail Narrative) - USD ($)	Sep. 02, 2020	Aug. 14, 2020	May 02, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 14, 2020	May 14, 2020	Mar. 31, 2020
Notes payable and accrued interest - Related party				$ 32,884		$ 32,884			$ 61,255
Notes payable principle Amount			$ 38,665
Notes payable				296,801		$ 296,801			$ 76,350
Debt interest rate			1.00%
Debt instrument maturity date			May 1, 2022			Apr. 30, 2020
Value of common stock issued				25,382	$ 537,703
Three Directors [Member]
Notes payable principle Amount							$ 25,000
Accrued Interest							$ 382
Convertible price per share							$ .2538
Amended Promissory Note [Member]
Notes payable principle Amount				59,642		$ 59,642
Accrued Interest				1,417		1,417
Amended Promissory Note [Member] | David B Masters [Member]
Additional term	2 years
Notes payable principle Amount	$ 59,642
Accrued Interest	6,058
Notes payable	$ 65,700			195,000		195,000
Debt interest rate	8.00%
Debt default interest rate	20.00%
Annual monthly payments	$ 3,100
Debt instrument convenient gross proceeds from product sale	1,500,000
Debt instrument convenient proceeds from equity sales	1,500,000
Claim on past accrued salary				195,000		195,000
Promissory Note [Member]
Notes payable principle Amount				192,500		192,500
Accrued Interest				$ 417		$ 417
Promissory Note [Member] | David B Masters [Member]
Notes payable principle Amount	$ 195,000
Debt interest rate	3.00%
Debt instrument maturity date	Aug. 31, 2022
Annual monthly payments	$ 4,000
Debt instrument convenient gross proceeds from product sale	3,500,000
Claim on past accrued salary	195,000
Debt modification	$ 195,000
Convertible Notes Payable [Member] | Three Directors [Member]
Notes payable principle Amount								$ 25,000
Accrued Interest		$ 382
Debt interest rate								6.00%
Outstanding balance		$ 25,382
Convertible price per share		$ .2538
Shares of common stock issued		100,010
Value of common stock issued		$ 25,383

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Details Narrative) - USD ($)	Sep. 30, 2020	Mar. 31, 2020
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$ 751,365	$ 794,057
Accounts payable	517,278	556,653
Tenant improvement allowance	7,500
Accrued liabilities	226,588	237,404
Accrued salaries and related payroll taxes payable	$ 15,209	$ 22,025

PPP Loan (Detail Narrative)

PPP Loan (Detail Narrative) - USD ($)	May 02, 2020	Sep. 30, 2020
Debt Disclosure [Abstract]
Proceeds from paycheck protection program loan	$ 38,665
Outstanding balance	38,827
Debt principal amount	38,665
Accrued interest	$ 162
Interest rate	1.00%
Debt Maturity	May 1, 2022	Apr. 30, 2020

Accrued Expenses - Related Pa_2

Accrued Expenses - Related Party (Details Narrative) - USD ($)	Sep. 30, 2020	Sep. 02, 2020	Mar. 31, 2020
Notes payable	$ 296,801		$ 76,350
Accounts payable	517,278		556,653
Accrued salaries and payroll taxes payable	15,209		22,025
Amended Promissory Note [Member] | David B Masters [Member]
Notes payable	195,000	$ 65,700
Claim on past accrued salary	195,000
Related Party [Member]
Accrued expenses, related party	$ 21,270		252,607
Accounts payable			38,954
Accrued salaries and payroll taxes payable			$ 213,653

Common Stock and Warrants (Deta

Common Stock and Warrants (Details Narrative)	Nov. 16, 2020shares	Oct. 23, 2020	Sep. 14, 2020USD ($)$ / sharesshares	Jul. 24, 2020USD ($)$ / sharesshares	Jul. 10, 2020shares	Jul. 02, 2020USD ($)$ / sharesshares	Sep. 18, 2019USD ($)shares	Sep. 13, 2019USD ($)shares	Jul. 13, 2019USD ($)shares	Oct. 31, 2020	Sep. 30, 2020USD ($)Integer$ / sharesshares	Sep. 30, 2020USD ($)Integer$ / sharesshares	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)Integer$ / sharesshares	Jun. 30, 2019USD ($)	Sep. 30, 2020USD ($)Integer$ / sharesshares	Sep. 30, 2019USD ($)Integer$ / sharesshares	Mar. 31, 2020USD ($)$ / sharesshares	Oct. 30, 2020shares	Oct. 28, 2020shares	Sep. 02, 2020USD ($)$ / sharesshares	Jun. 15, 2020USD ($)$ / sharesshares	May 02, 2020USD ($)
Reverse stock split, description		On October 23, 2020, the Company approved and declared a reverse stock split of all its outstanding common stock at a ratio of 1-for-4 shares; this reverse stock split has not yet been made effective.
Number of shares issued																	466,086	1,763,872
Value of shares issued | $
Number of shares issued for compensation
Value of shares issued for compensation | $												$ 653,863	$ 183,244		237,278	$ 190,801	$ 837,107
Debt Principal | $																								$ 38,665
Shares issued description																	80,000 shares with a relative value of $34,709 pursuant to a purchase of 80,000 units whereby a unit is made up of 1 share of common stock and ½ warrant. The value of $34,709 along with the relative value of the warrants associated with this transaction of $17,291 ($52,000 total) was recorded during the quarter ended March 31, 2020 to Common Stock Subscribed and moved to Additional Paid in Capital and Capital Stock upon receipt of funds and issuance of shares of common stock during the quarter ended June 30, 2020;
Fair value of warrants | $																	$ 91,500
Number of shares issued for services							270,000		108,000
Number of shares issued for services, value | $							$ 102,000		$ 120,000
Loss on extinguishment of debt | $															$ (81,738)			$ (81,738)
Warrant expense recognized | $																	412,000
Stock-based compensation | $																	$ 837,107	$ 326,078
Expected Volatility [Member]
Warrant measurement inputs | Integer															313			313
Expected Volatility [Member] | Minimum [Member]
Warrant measurement inputs | Integer											350	350					350
Expected Volatility [Member] | Maximum [Member]
Warrant measurement inputs | Integer											433	433					433
Risk-Free Interest [Member]
Warrant measurement inputs | Integer															2.30			2.30
Risk-Free Interest [Member] | Minimum [Member]
Warrant measurement inputs | Integer											0.29	0.29					0.29
Risk-Free Interest [Member] | Maximum [Member]
Warrant measurement inputs | Integer											1.16	1.16					1.16
RedDiamond Partners, LLC [Member]
Warrants to purchase shares of common stock											557,143	557,143					557,143
Debt Principal | $											$ 352,941	$ 352,941					$ 352,941
Accrued interest | $											$ 52,941	$ 52,941					$ 52,941
Conversion price | $ / shares											$ .28	$ .28					$ .28
Warrants [Member]
Warrants to purchase shares of common stock											27,237	27,237					27,237
Warrant to purchase of common stock, value | $											$ 11,984	$ 11,984					$ 11,984
Warrants exercise price | $ / shares											$ .40	$ .40					$ .40
Warrant granted to purchase shares of common stock																	240,627	270,000
Warrant granted to purchase shares of common stock, value | $																	$ 443,108
Warrants exercise term											5 years	5 years					5 years
Cancellation of warrants to purchase common stock																		324,000
RDCN Warrants [Member] | RedDiamond Partners, LLC [Member]
Warrants to purchase shares of common stock																							557,143
Warrant to purchase of common stock, value | $																							$ 234,000
Warrants exercise price | $ / shares																							$ .35
Warrants exercise term																							5 years
Think Warrants [Member]
Warrants to purchase shares of common stock																							75,000
Warrant to purchase of common stock, value | $																							$ 31,500
Warrants exercise price | $ / shares																							$ .35
Warrants exercise term																							5 years
Warrant One [Member]
Warrants to purchase shares of common stock											29,762	29,762					29,762
Warrant to purchase of common stock, value | $											$ 13,095	$ 13,095					$ 13,095
Warrants exercise price | $ / shares											$ .40	$ .40					$ .40
Warrants exercise term											5 years	5 years					5 years
Cancellation of warrants to purchase common stock																		54,000
Warrant Two [Member]
Warrants to purchase shares of common stock											8,349	8,349					8,349
Warrant to purchase of common stock, value | $											$ 3,674	$ 3,674					$ 3,674
Warrants exercise price | $ / shares											$ .40	$ .40					$ .40
Warrants exercise term											5 years	5 years					5 years
Warrant [Member]
Warrants to purchase shares of common stock															270,000			270,000
Warrant to purchase of common stock, value | $															$ 300,770			$ 300,770
Warrant granted to purchase shares of common stock																	290,348		1,905,700
Warrant expense recognized | $																		$ 117,144
Warrant [Member] | Minimum [Member]
Warrants exercise price | $ / shares											$ .30	$ .30			$ 0.33		$ .30	$ 0.33
Warrant [Member] | Maximum [Member]
Warrants exercise price | $ / shares											$ 2.22	$ 2.22			$ 3.89		$ 2.22	$ 3.89
Accrued Expenses - Related Party [Member]
Reduction in accrued compensation | $																		$ 375,936
Accounts Payable and Accrued Expenses [Member]
Reduction in accrued compensation | $																		$ 80,029
One Share of Common Stock and 1/2 Warrant Share [Member]
Warrants to purchase shares of common stock														80,000					80,000
Warrant to purchase of common stock, value | $														$ 34,709					$ 34,709
Fair value of warrants | $														34,709
Warrant transaction cost | $														$ 17,291
Video Marketing Services [Member]
Number of shares issued for compensation																	120,000
Value of shares issued for compensation | $																	$ 40,680
Two Service Provider [Member]
Number of shares issued for services						50,000
Number of shares issued for services, value | $						$ 22,000
Marketing and Investor Relations Service Provider [Member]
Number of shares issued for services						40,000
Number of shares issued for services, value | $						$ 17,600
Legal Service Provider [Member]
Number of shares issued for services						10,000
Number of shares issued for services, value | $						$ 4,400
One Warrant Holder [Member]
Number of shares issued				61,027
Value of shares issued | $				$ 12,053
Warrants converted on cashless basis				100,000
Warrants exercise price | $ / shares				$ .30
Four Accredited Investors [Member]
Number of shares issued											904,288
Value of shares issued | $											$ 316,500
Directors and Officers [Member]
Number of shares issued for compensation			649,007
Value of shares issued for compensation | $			$ 486,755
John Lai [Member]
Number of shares issued for compensation			134,479
Warrants to purchase shares of common stock											90,000	90,000					90,000
Warrant to purchase of common stock, value | $											$ 28,964	$ 28,964					$ 28,964
Value of warrant vested | $																	$ 10,000,000
Warrants exercise price | $ / shares											$ .35	$ .35					$ .35
Warrants exercise term											5 years	5 years					5 years
John Lai [Member] | Settlement Agreement [Member]
Number of shares issued for compensation																		348,000
Value of shares issued for compensation | $																		$ 116,000
Shares holding term																		3 years
John Carruth [Member]
Number of shares issued for compensation			104,867
John Dolan [Member]
Number of shares issued for compensation			91,976
John Dolan [Member] | Settlement Agreement [Member]
Number of shares issued for compensation																		204,000
Value of shares issued for compensation | $																		$ 68,000
Shares holding term																		3 years
Gregory Cash [Member]
Number of shares issued for compensation			43,157
David Deming [Member]
Number of shares issued for compensation			42,848
Robert Rudelius [Member]
Number of shares issued for compensation			42,509
Robert Rudelius [Member] | Warrant [Member]
Warrants to purchase shares of common stock						7,500
Warrant to purchase of common stock, value | $						$ 3,300
Warrants exercise price | $ / shares						$ 0.40
Warrants exercise term						5 years
Randy Meyer [Member]
Number of shares issued for compensation			42,197
Jim Martin [Member]
Number of shares issued for compensation			37,205
Scott Johnson [Member]
Number of shares issued for compensation			37,197
Joseph Jasper [Member]
Number of shares issued for compensation			36,835
Joseph Jasper [Member] | Warrant [Member]
Warrants to purchase shares of common stock						7,500
Warrant to purchase of common stock, value | $						$ 3,300
Warrants exercise price | $ / shares						$ 0.40
Warrants exercise term						5 years
David Masters [Member]
Number of shares issued for compensation			35,737
David Masters [Member] | Warrant [Member]
Warrants to purchase shares of common stock																						120,000
Warrant to purchase of common stock, value | $																						$ 96,000
Warrants exercise price | $ / shares																						$ .35
Warrants exercise term																						5 years
Three Directors [Member]
Number of shares issued for compensation			100,010
Value of shares issued for compensation | $			$ 25,383
Conversion of notes | $			25,382
Debt Principal | $			25,000
Accrued interest | $			$ 382
Conversion price | $ / shares			$ .2538
Randall Meyer [Member] | Settlement Agreement [Member]
Number of shares issued for compensation																		575,808
Value of shares issued for compensation | $																		$ 191,936
Shares holding term																		3 years
Former Employee [Member] | Settlement Agreement [Member]
Number of shares issued for compensation																		168,060
Value of shares issued for compensation | $																		$ 80,029
One Shareholder [Member]
Number of stock sold								360,000
Value of stock sold | $								$ 100,000
One Investor [Member] | Warrants [Member]
Warrants to purchase shares of common stock														40,000					40,000
Warrant to purchase of common stock, value | $														$ 17,291					$ 17,291
Warrants exercise price | $ / shares														$ 4					$ 4
Warrants exercise term														3 years					3 years
Messrs. Scott Johnson, Gregory Cash, and James Martin [Member] | Warrants [Member]
Warrants to purchase shares of common stock															270,000			270,000
Warrant to purchase of common stock, value | $															$ 119,954			$ 119,954
Warrants exercise price | $ / shares															$ .33			$ .33
Warrants exercise term															5 years			5 years
Vesting of warrants																		135,000
2020 Equity Incentive Plan [Member]
Number of shares authorized					4,000,000
Expiration date					Jul. 10, 2030
Shares issued
2020 Equity Incentive Plan [Member] | Nonemployee Director [Member]
Maximum number of shares per employee					100,000
Subsequent Event [Member]
Reverse stock split, description										The Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was effected on November 12, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000. Pursuant to this reverse stock split, each four (4) shares of PetVivo's outstanding common stock, $.001 par value per share, was combined and converted into one (1) post-split outstanding shares of common stock, $.001 par value per share
Number of shares issued
Subsequent Event [Member] | One Warrant Holder [Member]
Warrants to purchase shares of common stock																					27,000
Subsequent Event [Member] | John Lai [Member]
Warrants to purchase shares of common stock																				168,750

Common Stock and Warrants - Sch

Common Stock and Warrants - Schedule of Warrant Activity (Details) - Warrant [Member] - $ / shares	6 Months Ended	12 Months Ended
	Sep. 30, 2020	Mar. 31, 2020
Number of Warrants, Outstanding, Beginning Balance	4,901,119	3,818,919
Number of Warrants, Granted	290,348	1,905,700
Number of Warrants, Cashless warrant exercises	(100,000)	(337,500)
Number of Warrants, Expired	(36,000)	(90,000)
Number of Warrants, Cancelled		(396,000)
Number of Warrants, Issued in conjunction with convertible debt	632,143
Number of Warrants, Sold	40,000
Number of Warrants, Outstanding, Ending Balance	5,727,610	4,901,119
Weighted-Average Exercise Price, Outstanding, Beginning Balance	$ 2.12	$ 2.20
Weighted-Average Exercise Price, Granted	0.37	2.07
Weighted-Average Exercise Price, Cashless Conversions	0.30	1.27
Weighted-Average Exercise Price, Expired	3.89	2.22
Weighted-Average Exercise Price, Cancelled		2.32
Weighted-Average Exercise Price, Issued in conjunction with convertible debt	0.35
Weighted-Average Exercise Price, Sold	1
Weighted-Average Exercise Price, Outstanding, Ending Balance	$ 0.50	$ 2.12
Warrants Exercisable, Outstanding, Beginning Balance	4,072,369	3,035,035
Warrants Exercisable, Outstanding, Ending Balance	5,073,860	4,072,369
Weighted-Average Exercisable Price, Outstanding, Beginning Balance	$ 0.53	$ 0.54
Weighted-Average Exercisable Price, Outstanding, Ending Balance	$ 0.48	$ 0.53

Common Stock and Warrants - S_2

Common Stock and Warrants - Schedule of Range of Warrant Prices (Details) - Warrant [Member] - $ / shares	6 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Mar. 31, 2019
Number of Warrants, Outstanding	5,727,610	4,901,119	3,818,919
Weighted-Average Exercise Price, outstanding	$ 0.50	$ 2.12	$ 2.20
Weighted-Average Remaining Contractual Life (Years), Outstanding	3 years 5 months 9 days
Number of Warrants, Exercisable	5,073,860	4,072,369	3,035,035
Weighted-Average Exercise Price, Exercisable	$ 0.48	$ 0.53	$ 0.54
Range One [Member]
Range of Warrant Exercise Price, Lower limit	1.20
Range of Warrant Exercise Price, Upper limit	$ 2
Number of Warrants, Outstanding	3,122,192
Weighted-Average Exercise Price, outstanding	$ 0.34
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 4 months 6 days
Number of Warrants, Exercisable	3,278,442
Weighted-Average Exercise Price, Exercisable	$ 0.33
Range Two [Member]
Range of Warrant Exercise Price, Lower limit	2.01
Range of Warrant Exercise Price, Upper limit	$ 4
Number of Warrants, Outstanding	2,145,739
Weighted-Average Exercise Price, outstanding	$ 0.58
Weighted-Average Remaining Contractual Life (Years), Outstanding	2 years 5 months 1 day
Number of Warrants, Exercisable	1,335,739
Weighted-Average Exercise Price, Exercisable	$ 0.60
Range Three [Member]
Range of Warrant Exercise Price, Lower limit	4.01
Range of Warrant Exercise Price, Upper limit	$ 10
Number of Warrants, Outstanding	459,679
Weighted-Average Exercise Price, outstanding	$ 1.23
Weighted-Average Remaining Contractual Life (Years), Outstanding	2 years 4 days
Number of Warrants, Exercisable	459,679
Weighted-Average Exercise Price, Exercisable	$ 1.23

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Nov. 05, 2020	Nov. 04, 2020	Oct. 30, 2020	Oct. 28, 2020	Oct. 26, 2020	Oct. 25, 2020	Oct. 15, 2020	Oct. 13, 2020	Oct. 31, 2020	Sep. 30, 2020	Sep. 02, 2020	May 02, 2020	Sep. 30, 2019
Debt Principal												$ 38,665
Subsequent Event [Member]
Issuance of stock								$ 10,000,000
Weighted average, exercise price									$ 5.04
Promissory Note [Member]
Debt Principal										$ 192,500
Accrued interest										417
OID Convertible Notes [Member]
Debt conversion, converted instrument amount										365,809
Accrued interest										$ 12,868			$ 0
OID Convertible Notes [Member] | Subsequent Event [Member]
Debt conversion, converted instrument amount					$ 368,995
Debt Principal					352,941
Accrued interest					$ 16,054
Outstanding principal and interest converted into common stock, shares					1,054,271
Converted shares, price per share					$ .35
David B Masters [Member] | Promissory Note [Member]
Debt Principal											$ 195,000
David B Masters [Member] | Promissory Note [Member] | Subsequent Event [Member]
Debt conversion, converted instrument amount							$ 192,500
Conversion fee							$ 3,500
One Warrant Holder [Member] | Subsequent Event [Member]
Warrants exercised shares	27,000	27,000		51,429	13,500	54,000
Warrants exercised value	$ 15,000	$ 15,000		$ 28,571	$ 7,500	$ 30,000
Outstanding principal and interest converted into common stock, shares				3,172
Converted shares, price per share				$ 1.11
Warrants for common stock				27,000
Weighted average, exercise price				$ 1.259
John Lai [Member]
Warrants for common stock										90,000
John Lai [Member] | Subsequent Event [Member]
Outstanding principal and interest converted into common stock, shares			129,387
Converted shares, price per share			$ .33
Warrants for common stock			168,750
Weighted average, exercise price			$ 1.429